@article {Furr-Stimming1620作者={艾琳Furr-Stimming维克多演唱和杀伤力谢夫和罗莎Willock主儿Ribalov和萨拉·布莱顿和山姆狮子座},title ={舞蹈病严重性随时间变化在亨廷顿病和亨廷顿病阶段(p1 - 11.010)},体积={100},数量={17补充2},elocation-id = {1620} = {2023}, doi = {10.1212 / WNL。出版商0000000000202019}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:描述舞蹈病严重程度随着时间的推移,在个人与亨廷顿病(HD)分层总功能能力首页(交通)。背景:舞蹈病,最常见的运动症状在高清,消极地影响生活质量和交通。解决舞蹈病是至关重要的减少运动症状在高清的负担。舞蹈病报道增加最初,高原,随着时间和潜在的减少;然而,纵向数据评估舞蹈病严重性疾病阶段是有限的。设计/方法:参与者从Enroll-HD成年人,一个全球性、纵向,观察注册为个人或高清的风险(数据削减2013 {\ textendash} 2020年10月31日)。清单由基线人口分层交通分数代表高清阶段(交通7 {\ textendash} 13 /阶段1 {\ textendash} 2(早期),3 {\ textendash} 6 /第三阶段(中间),0 {\ textendash} 2 /阶段4 {\ textendash} 5(已故))。舞蹈病严重性评估了总最大舞蹈病(TMC)评分基线和年度互访。> = 4年随访患者选择估计舞蹈病进展。结果:显示人口被高清分组阶段:早,n = 7441;中间,n = 2330;晚了,n = 1120。 Baseline TMC scores (mean [SD]) increased as HD stage progressed (early, 8.0 [4.7]; middle, 10.4 [5.8]; late, 10.6 [6.9]). For participants with >=4 years of follow-up (n=1271), TMC scores increased over time in early-stage HD (n=963; years 1{\textendash}2, 8.5 [5.0]; years 2{\textendash}3, 9.1 [5.3]; years 3{\textendash}4, 9.5 [5.6]), but plateaued at high levels in middle- (n=222; 10.6 [5.3]; 10.6 [6.0]; 10.1 [5.7], respectively) and late-stage HD (n=86; 10.4 [6.6]; 9.8 [6.9]; 9.7 [6.2]).Conclusions: Chorea severity increased in early-stage HD, and plateaued in middle- and late-stage HD. Chorea severity did not decrease longitudinally in any stage; however, the limited sample size for the follow-up period should be considered. These results support the need for increased awareness about the potential for persistent chorea in late-stage HD.Disclosure: Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Pharmaceuticals. The institution of Dr. Furr-Stimming has received research support from Cures within Reach. The institution of Dr. Furr-Stimming has received research support from Huntington{\textquoteright}s Disease Society of America. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Reshef has received personal compensation for serving as an employee of Teva. Ms. Willock has received personal compensation for serving as an employee of HCD Economics. Rinat Ribalov has received personal compensation for serving as an employee of TEVA. Miss Brighton has nothing to disclose. Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/100/17_Supplement_2/1620}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }